Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Schizophrenia, Bipolar Disorder, Major Depression
Interventions: Person-Centered Care, Measurement-Based Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Pittsburgh, Pennsylvania

Conditions: Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
Interventions: Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Major Depressive Disorder, Attention-deficit Hyperactivity Disorder (ADHD)
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Major Depressive Disorder (MDD)
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Depressive Disorder
Interventions: Saredutant succinate (SR48968C); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Depression
Interventions: Escitalopram, Bupropion; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
Interventions: LTFUS to SCC, LTFUS to ALIC; Device
Lead sponsor: Brian Mickey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Asthma, Major Depressive Disorder
Interventions: Non-Interventional; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years to 70 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Social Phobia, Panic Disorder, Agoraphobia, Major Depressive Disorder
Interventions: Mindful Self-Compassion; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
Interventions: LFMS; Device
Lead sponsor: Tal Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more

Conditions: Depression
Interventions: iTBS Device/Motor Threshold Coil, iTBS Device/Treatment Coil; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder
Interventions: Genecept Assay; Device
Lead sponsor: Genomind, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Treatment Resistant Major Depression
Interventions: Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 22 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Major Depressive Disorder, Depression
Interventions: REL-1017, Placebo; Drug
Lead sponsor: Levomecor Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Accelerated rTMS treatment; Device
Lead sponsor: NeuroQore Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Jose, California

Conditions: Major Depressive Disorder
Interventions: Selegiline Transdermal System, Placebo; Drug
Lead sponsor: Somerset Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Dothan, Alabama • National City, California • San Diego, California + 17 more

Conditions: Glioma of Brain
Interventions: Mirtazapine (Remeron); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Orange, California

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: PDC-1421 Capsule, placebo; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depression, Bipolar Depression, Schizoaffective Disorder
Interventions: Razadyne, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression / Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions: Intern Health Study behavioral change mobile notification; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Person-Centered Versus Measurement-Based Care in Mental Health

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Personalized Ultrasonic Brain Stimulation for Depression (R61)

Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators

Mindful Self-Compassion for Anxiety Disorders and Depression

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

iTBS for Adolescent Depression: An Open Label Study Evaluating Safety and Efficacy of Treatment

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

Establishing Mobile Transcranial Magnetic Stimulation

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

The Treatment of Children and Adolescents With Treatment-Resistant Depression

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Intern Health Study 2026